Current status of the development of trans-platinum antitumor drugs

被引:128
作者
Pérez, JM
Fuertes, MA
Alonso, C
Navarro-Ranninger, C
机构
[1] Univ Autonoma Madrid, Fac Ciencias, Dept Quim Inorgan, Madrid 28049, Spain
[2] Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC,UAM, E-28049 Madrid, Spain
关键词
novel; trans-platinum; antitumor complexes;
D O I
10.1016/S1040-8428(00)00053-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The discovery in the 1990s of several trans-Pt complexes with in vitro and in vivo activity against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the structure-activity relationships for platinum antiturnor drugs. Because the determinant factors of cytotoxic activity of trans-platinum complexes do not follow the same patterns as those found for cisplatin and its analogues, the differences in cellular and biochemical pharmacology between trans-platinum antitumor complexes and cisplatin might be systematically exploited to design novel trans-platinum complexes with a clinical profile complementary to that of cisplatin and related analogues. Therefore, there may exist a novel molecular rationale for new platinum antitumor drugs development in the twenty-first century. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:109 / 120
页数:12
相关论文
共 59 条
[1]  
Boccarelli A, 1999, ANTI-CANCER DRUG DES, V14, P253
[2]  
Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1
[3]   DNA INTERSTRAND CROSS-LINKS OF TRANS-DIAMMINEDICHLOROPLATINUM(II) ARE PREFERENTIALLY FORMED BETWEEN GUANINE AND COMPLEMENTARY CYTOSINE RESIDUES [J].
BRABEC, V ;
LENG, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5345-5349
[4]   DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent [J].
Brabec, V ;
Kaspárková, J ;
Vrána, O ;
Nováková, O ;
Cox, JW ;
Qu, Y ;
Farrell, N .
BIOCHEMISTRY, 1999, 38 (21) :6781-6790
[5]   DNA adducts of antitumor trans-[PtCl2 (E-imino ether)(2)] [J].
Brabec, V ;
Vrana, O ;
Novakova, O ;
Kleinwachter, V ;
Intini, FP ;
Coluccia, M ;
Natile, G .
NUCLEIC ACIDS RESEARCH, 1996, 24 (02) :336-341
[6]   ISOLATION AND CHARACTERIZATION OF HUMAN CDNA CLONES ENCODING A HIGH MOBILITY GROUP BOX PROTEIN THAT RECOGNIZES STRUCTURAL DISTORTIONS TO DNA CAUSED BY BINDING OF THE ANTICANCER AGENT CISPLATIN [J].
BRUHN, SL ;
PIL, PM ;
ESSIGMANN, JM ;
HOUSMAN, DE ;
LIPPARD, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (06) :2307-2311
[7]   A TRANS-PLATINUM COMPLEX SHOWING HIGHER ANTITUMOR-ACTIVITY THAN THE CIS CONGENERS [J].
COLUCCIA, M ;
NASSI, A ;
LOSETO, F ;
BOCCARELLI, A ;
MARIGGIO, MA ;
GIORDANO, D ;
INTINI, FP ;
CAPUTO, P ;
NATILE, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (04) :510-512
[8]  
Coluccia M, 1999, INT J ONCOL, V15, P1039
[9]   In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands [J].
Coluccia, M ;
Nassi, A ;
Boccarelli, A ;
Giordano, D ;
Cardellicchio, N ;
Locker, D ;
Leng, M ;
Sivo, M ;
Intini, FP ;
Natile, G .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1999, 77 (1-2) :31-35
[10]   Platinum(II) complexes containing iminoethers: A trans platinum antitumour agent [J].
Coluccia, M ;
Boccarelli, A ;
Mariggio, MA ;
Cardellicchio, N ;
Caputo, P ;
Intini, FP ;
Natile, G .
CHEMICO-BIOLOGICAL INTERACTIONS, 1995, 98 (03) :251-266